Haemonetics Corp (HAE) Stock Analysis
Verdict: BUY
The CSL Plasma agreement secures long-term volume growth, but the recent 16% price spike leaves the stock technically overextended.
Investment score: 68/100
Analysis as of
Is Haemonetics Corp stock worth reviewing? AI model thesis
The model score of 68/100 falls in the BUY range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Haemonetics Corp opportunities and risks
What speaks for HAE
- CSL Plasma Agreement Expansion
What speaks against HAE
- Non-Exclusive Contract Limitations
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HAE | 50.8x | 3.5x | 21.8x | 57.4% | 7.1% | 6.1% |
| COO | 64.2x | 3.5x | 19.7x | 64.4% | 5.6% | 3.9% |
| ALGN | 29.2x | 2.9x | 14.0x | 66.5% | 10.0% | 6.3% |
| LNTH | 23.8x | 4.2x | 14.1x | 60.1% | 17.7% | 7.8% |
| MMED | n/a | 2.3x | 240.2x | 52.9% | -21.7% | -3.4% |
| MMSI | 36.4x | 3.4x | 15.7x | 49.5% | 9.2% | 3.8% |
| Peer median | 29.2x | 3.4x | 15.7x | 60.1% | 9.2% | 3.9% |
Frequently asked questions about Haemonetics Corp (HAE)
Is HAE stock a good investment?
The cached TradeMates AI model rates Haemonetics Corp as BUY with an investment score of 68/100. The model score of 68/100 falls in the BUY range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is HAE stock a buy?
The TradeMates model verdict for HAE is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.